Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Construction in Progress (2019 - 2024)

ENDRA Life Sciences has reported Construction in Progress over the past 3 years, most recently at $107682.0 for Q4 2021.

  • Quarterly Construction in Progress rose 35.95% to $107682.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $107682.0 through Dec 2021, up 35.95% year-over-year, with the annual reading at $107682.0 for FY2021, 35.95% up from the prior year.
  • Construction in Progress was $107682.0 for Q4 2021 at ENDRA Life Sciences, up from $79207.0 in the prior quarter.
  • Over five years, Construction in Progress peaked at $107682.0 in Q4 2021 and troughed at $43596.0 in Q4 2019.
  • The 3-year median for Construction in Progress is $79207.0 (2020), against an average of $76828.3.
  • Year-over-year, Construction in Progress surged 81.68% in 2020 and then soared 35.95% in 2021.
  • A 3-year view of Construction in Progress shows it stood at $43596.0 in 2019, then soared by 81.68% to $79207.0 in 2020, then soared by 35.95% to $107682.0 in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Construction in Progress are $107682.0 (Q4 2021), $79207.0 (Q4 2020), and $43596.0 (Q4 2019).